Terashima M, Hayashi K, Fukushima M, Ide H, Iizuka T, Kakegawa T, Ando N, Tanaka O, Shinoda M, Isono K, Ishida K, Ikeuchi S, Endo M, Takiyama W, Yanagawa T
Department of Surgery, Iwate Medical University, Morioka, Japan.
Br J Cancer. 1996 Jul;74(1):73-7. doi: 10.1038/bjc.1996.318.
A total of 83 specimens of surgically resected tumours from 78 patients with oesophageal cancer were assayed for drug sensitivity using an adhesive tumour cell culture system (LifeTrac CSA assay). Seventyone of 83 specimens had a sufficient number of cells to permit growth in culture and 57 of 71 (80%) were evaluable for drug response. Cells (3 x 10(3) ml-1 well-1) were cultured for 14 days and exposed to drugs on days 3-8. Growing cells were confirmed as cancer cells by immunohistochemical staining. IC90 values against several anti-cancer drugs were determined and population distributions of IC90 for each drug served as the basis for judging sensitivity. The 10th percentiles of IC90 (microgram ml-1) for CDDP, 5-FU, DOX, CPM, MTX, VP16, IFOS, VDS, BLM and CDDP + 5-FU were 0.3, 0.16, 0.005, 0.9, 0.006, 0.09, 0.8, 0.006, 0.04 and 0.15 + 0.09 respectively. The population distribution of IC90 against each drug showed a specific pattern that was very similar among histopathological gradings and stages of the disease. This system appeared to be a clinically applicable drug sensitivity test for human oesophageal cancer.
使用黏附肿瘤细胞培养系统（LifeTrac CSA检测法）对78例食管癌患者手术切除的83个肿瘤标本进行药物敏感性检测。83个标本中有71个含有足够数量的细胞可在培养中生长，71个中的57个（80%）可评估药物反应。将细胞（3×10³个/毫升孔）培养14天，并在第3 - 8天暴露于药物。通过免疫组织化学染色确认生长的细胞为癌细胞。测定了几种抗癌药物的IC90值，并以每种药物IC90的群体分布作为判断敏感性的基础。顺铂、5-氟尿嘧啶、阿霉素、环磷酰胺、甲氨蝶呤、依托泊苷、异环磷酰胺、长春地辛、博来霉素和顺铂 + 5-氟尿嘧啶的IC90（微克/毫升）第10百分位数分别为0.3、0.16、0.005、0.9、0.006、0.09、0.8、0.006、0.04和0.15 + 0.09。每种药物的IC90群体分布呈现出一种特定模式，在疾病的组织病理学分级和分期中非常相似。该系统似乎是一种适用于临床的人食管癌药物敏感性检测方法。
